Dynamics of HHV-8 plasma viremia and human DNA plasma contamination, PBMC HHV-8 load and anti–HHV-8 lytic Ab titers, and dynamics of HHV-8 replication and CD4 and CD8 T-cell counts in one IL-2–treated patient in whom KS developed.

(A,B) Plasma load of HHV-8 DNA (○) and β-actin (♦), HHV-8 load of PBMCs (■), and anti–HHV-8 lytic antigens Ab titer (▵), in patient 70. IL-2 was administered subcutaneously every 8 weeks for a total of 6 cycles (5 days twice a day for each cycle). KS lesions developed after 12 months of IL-2 therapy, 5 months after the last administration of IL-2. (C) Dynamics of HHV-8 plasma viremia (⋄) and CD4 (○) and CD8 (▵) T-cell counts during IL-2 therapy in patient 70.